AtaiBeckley Inc (ATAI)
NASDAQHealth CareBiotechnologySnapshot 2026-07-09
$5.17-3.00%
Close 2026-07-10 · 1-day change
Reading ATAI? Create a free portfolio, then add this holding for ongoing Reports and tracking. No credit card.
Create your account →NASDAQHealth CareBiotechnologySnapshot 2026-07-09
Reading ATAI? Create a free portfolio, then add this holding for ongoing Reports and tracking. No credit card.
Create your account →QuarterlyIQ Insights · ATAI
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended…
of this Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Entry into a Material Definitive Agreement. On March 6, 2026, AtaiBeckley Inc. (the “Company”) entered into an Open Market Sale Agreement SM (the “Sales Agreement”) with Jefferies LLC (“Jefferies”), pursuant to which the Company may issue and sell its common stock, par value $0.01 per share (the “Common Stock”), from time to time through an “at the market” equity offering program (the “Offering Program”) under which Jefferies will act as sales agent. The Common Stock to be sold pursuant to th…
Other Events. This Current Report on Form 8-K is being filed to provide additional information related to Beckley Psytech Limited, a company incorporated in England and Wales (“Beckley Psytech”), in connection with the previously announced share purchase agreement, dated June 2, 2025, by and among ATAI Beckley N.V., (f/k/a atai Life Sciences N.V.), a Dutch public company, Beckley Psytech and certain other parties thereto (as amended by the Side Letter Deed to the Share Purchase Agreement, dat…
Results of Operations and Financial Condition. On March 6, 2026, AtaiBeckley Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025 and provided a corporate and clinical update. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes…
Chief Financial Officer — Michael Faerm: Michael Faerm was appointed as the Chief Financial Officer, bringing in new leadership to the company.
Director — Cosmo Feilding-Mellen: Mr. Feilding-Mellen resigned from the board of directors with no stated disagreement.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.